Posts Tagged ‘digitalis toxicity’

Digitek®, used to treat heart conditions, recalled

Tuesday, May 13th, 2008

Digitek® has been voluntarily recalled by the manufacturer because some tablets with double the appropriate thickness may have been released. Those tablets may contain twice the approved level of active ingredient. This recall is being conducted with the knowledge of the Food and Drug Administration. For information about product returns and reimbursement, members should contact Actavis at 1-888-276-6166 Monday through Friday, 8 a.m. to 5 p.m. Eastern time or visit http://www.actavis.us/en/default.htm.

RightSource Customer Care is currently making outbound phone calls to members who have filled a prescription for Digitek®. For RightSource users with refills available for Digitek®, RightSource will refill their prescription with a medication that is not affected by the recall. RightSource users who do not have a Digitek® refill available should contact their doctor for a new mail-order prescription to submit to RightSource. We will also send affected RightSource customers a letter the week of May 19.

******************************************************************

If you would like to review your texas medicare supplement,
fill out the online form or pick up the phone and call me.

******************************************************************

In addition, we are sending letters the week of May 19 to members who purchased Digitek®. The Medication Therapy Management (MTM) team will make outbound calls to MTM-eligible members unless they have received a call from RightSource. Members should also be notified about the recall by their pharmacy.

Members are advised to:

  • Return Digitek® to the dispensing pharmacy* or contact Actavis at 1-888-276-6166
  • Ask their doctor or pharmacist about any medical concerns
  • Report signs of digitalis toxicity to their doctor

Note:*RightSource members are advised to return the recalled medication to the manufacturer’s designee.

Where can you find more information about this news?
Visit http://www.fda.gov/oc/po/firmrecalls/actavis04_08.html